Impact of Donor Clonal Haematopoiesis of Indeterminate Potential (CHIP) on Recipient Outcome Following Allogeneic Haematopoietic Stem Cell Transplantation (Allo-HSCT)

What this Trial Is About

Researchers are studying the impact of donor clonal hematopoiesis of indeterminate potential (CHIP) on the long-term outcomes of recipients who undergo allogeneic hematopoietic stem cell transplantation (HSCT). This study aims to understand the association between gene mutations in donors and how these may affect outcomes such as graft function, immune response, graft versus host disease, relapse, and survival. The research is conducted as a single-center prospective and retrospective cohort study at Queen Mary Hospital, Hong Kong. The study collects genetic information from donors at the time of peripheral blood stem cell or bone marrow donation, and from recipients at multiple time points after transplantation, including 1 month, 6 months, 12 months, and at any relapse or leukemia occurrence. Gene mutations and gene fusions are analyzed using next-generation sequencing and nanopore long-read sequencing technology. Data collection occurs through routine clinical visits and medical record reviews in a prospective, partial prospective/retrospective, or retrospective manner. Participants are followed regularly with data collected at donation, transplantation, and every six months post-transplant until death or study end. Researchers monitor outcomes including overall survival, progression-free survival, acute and chronic graft versus host disease, leukemia of donor origin, and cardiac and pulmonary complications over five years. The study involves detailed genetic profiling and long-term observation to assess how donor gene mutations influence recipient health after allogeneic HSCT.

Donor CHIP and Allogeneic HSCT Outcome